Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, and Medincell announced that the supplemental New Drug ...
Lowering the price of the 2.5 mg dose vial to $349 per month. Lowering the price of the 5 mg dose vial to $499 per month.
Last year marked an all-time record of 18 Food and Drug Administration (FDA) biosimilar approvals, bringing the total number ...
Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
AAM said the law sets up a process under which a drug would have price controls applied before a generic or biosimilar even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results